Human immunity in vitro - Solving immunogenicity and more

Advanced Drug Delivery Reviews

Volumn 69-70, Issue , 2014, Pages 103-122

  Giese, Christoph ^a   Marx, Uwe ^b  

^a PROBIOGEN AG   (Germany)

^b TECHNISCHE UNIVERSITÄT BERLIN   (Germany)

Author keywords

3D tissue culture; Adaptive immunity; Germinal centres; Human on a chip; Immunogenicity; Lymphoid follicles; Microfluidics; Microsystems; Native immunity; Organs on a chip

Indexed keywords

DRUG DELIVERY; MICROFLUIDICS; MICROSYSTEMS; THREE DIMENSIONAL; TISSUE CULTURE;

ADAPTIVE IMMUNITY; GERMINAL CENTRES; HUMAN-ON-A-CHIP; IMMUNOGENICITY; LYMPHOID FOLLICLES; NATIVE IMMUNITY; ORGANS-ON-A-CHIP;

IMMUNE SYSTEM;

ADAPTIVE IMMUNITY; BIOCHIP; BONE MARROW; CELL ADHESION; CELL MIGRATION; ENZYME LINKED IMMUNOSPOT ASSAY; GASTROINTESTINAL TRACT; GERMINAL CENTER; HUMAN; HUMAN ON A CHIP; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; INNATE IMMUNITY; LUNG; LYMPHOID ORGAN; LYMPHOID TISSUE; NONHUMAN; ORGANS ON A CHIP; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REVIEW; TISSUE STRUCTURE; ANIMAL; CULTURE TECHNIQUE; IMMUNOGENETICS; IMMUNOLOGY; ORGAN CULTURE TECHNIQUE; PROCEDURES; TRENDS;

ADAPTIVE IMMUNITY; ANIMALS; CELL CULTURE TECHNIQUES; HUMANS; IMMUNITY, INNATE; IMMUNOGENETIC PHENOMENA; ORGAN CULTURE TECHNIQUES;

EID: 84899974896     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2013.12.011     Document Type: Review

References (246)

1. Andrade F., Videira M., Ferreira D., Sosnik A., Sarmento B. Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases. Adv. Drug Deliv. Rev. 2013, 65:1816-1827.
2. Casals E., Pfaller T., Duschl A., Oostingh G.J., Puntes V. Time evolution of the nanoparticle protein corona. ACS Nano 2010, 4:3623-3632.
3. Oyewumi M.O., Kumar A., Cui Z. Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev. Vaccines 2011, 9:1095-1107.
4. Zolnik B.S., Stern S.T., Kaiser J.M., Heakal Y., Clogston J.D., Kester M., Mcneil S.E. Rapid distribution of liposomal short-chain ceramide in vitro and in vivo. Drug Metab. Dispos. 2008, 36:1709-1715.
5. Rosado-de-Castro P.H., Pimentel-Coelho P.M., Barbosa da Fonseca L.M., de Freitas G.R., Mendez-Otero R. The rise of cell therapy trials for stroke: review of published and registered studies. Stem Cells Dev. 2013, 22:2095-2111.
6. Wu R., Forget M.A., Chacon J., Bernatchez C., Haymaker C., Chen J.Q., Hwu P., Radvanyi L. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook. Cancer J. 2013, 18:160-175.
7. Weber J., Atkins M., Hwu P., Radvanyi L., Sznol M., Yee C. White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy. Clin. Cancer Res. 2011, 17:1664-1673.
8. Boateng J., Metthews K., Stevens H., Ecclestong G. Wound healing dressings and drug delivery systems: a review. J. Pharm. Sci. 2008, 97:2892-2923.
9. Bee J.S., Goletz T.J., Ragheb J.A. The future of protein particle characterization and understanding its potential to diminish the immunogenicity of biopharmaceuticals: a shared perspective. J. Pharm. Sci. 2012, 101:3580-3585.
10. Johnson R., Jiskoot W.I.M. Models for evaluation of relative immunogenic potential of protein particles in biopharmaceutical protein formulations. J. Pharm. Sci. 2012, 101:3586-3592.
11. Chirmule N., Jawa V., Meibohm B. Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy. AAPS J. 2012, 14:296-302.
12. Marszal E.W.A., Fowler E. Workshop on predictive science of the immunogenicity aspects of particles in biopharmaceutical products. J. Pharm. Sci. 2012, 101:3555-3559.
13. Rosenberg A.M.Y.S., Verthelyi D., Cherney B.W. Managing uncertainty: a perspective on risk pertaining to product quality attributes as they bear on immunogenicity. J. Pharm. Sci. 2012, 101:3560-3567.
14. Holloway C., Mueller-Berghaus J., Lima B.S., Lee S.L., Wyatt J.S., Nicholas J.M., Crommelin D.J. Scientific considerations for complex drugs in light of established and emerging regulatory guidance. Ann. N. Y. Acad. Sci. 2012, 1276:26-36.
15. Moghimi S.M., Andersen A.J., Ahmadvand D., Wibroe P.P., Andresen T.L., Hunter A.C. Material properties in complement activation. Adv. Drug Deliv. Rev. 2011, 63:1000-1007.
16. Szebeni J., Muggia F., Gabizon A., Barenholz Y. Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. Adv. Drug Deliv. Rev. 2011, 63:1020-1030.
17. Hamad I., Al-hanbali Kj O., Hunter A.C., Rutt K.J., Andresen T.L., Moghimi S.M. Switching of complement activation pathways at the nanosphere-serum interface: implications for stealth nanoparticle engineering. ACS Nano 2010, 4:6629-6638.
18. Moghimi S.M., Andersen A.J., Hashemi S.H., Lettiero B., Ahmadvand D., Hunter A.C., Andresen T.L., Hamad I., Szebeni J. Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes: the challenges ahead. J. Control. Release 2010, 146:175-181.
19. Chanan-Khan F.M., Szebeni A., Savay J., Liebs S., Rafique L., Alving N.M., Muggia C.R. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil(R)): possible role in hypersensitivity reactions. Ann. Oncol. 2003, 14:1430-1437.
20. Moghimi S.M., Hunter A.C., Murray J.C. Nanomedicine: current status and future prospects. FASEB J. 2005, 19:311-330.
21. Jiskoot W., van Schie R.M.F., Carstens M.G., Schellekens H. Immunological risk of injectable drug delivery systems. Pharm. Res. 2009, 26(2009):1303-1314.
22. Baker M.P., Reynolds H.M., Lumicisi B., Bryson C.J. Immunogenicity of protein therapeutics: the key causes, consequences and challenges. Self Nonself 2010, 1:314-322.
23. Jiskoot W.I.M., Randolph T.W., Volkin D.B., Middaugh C.R., Oneich C.S.C.H., Winter G., Friess W., Crommelin D.J.A., Carpenter J.F. Protein instability and immunogenicity: roadblocks to clinical application of injectable. J. Pharm. Sci. 2012, 101:946-954.
24. Dobrovolskaia M.A., Mcneil S.E. Handbook of Immunological Properties of Engineered Nanomaterials 2013, World Scientific Publishing Co. Pte Ltd.
25. Leist M., Hartung T. Inflammatory findings on species extrapolations: humans are definitely no 70-kg mice. Arch. Toxicol. 2013, 87:563-567.
26. Suntharalingam G., Perry M., Ward S., Brett S.J., Castello-cortes A., Brunner M.D., Panoskaltsis N. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. NEJM 2006, 355:1018-1028.
27. Clair E.W. The calm after the cytokine storm: lessons from the TGN1412 trial. J. Clin. Invest. 2008, 118:2006-2009.
28. Stebbings R., Findlay L., Edwards C., Eastwood D., Bird C., North D., Mistry Y., Dilger P., Liefooghe E., Cludts I., Fox B., Tarrant G., Robinson J., Meager T., Dolman C., Thorpe S.J., Bristow A., Wadhwa M., Thorpe R., Poole S. 'Cytokine storm' in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics. J. Immunol. 2007, 179:3325-3331.
29. Materne E.M., Tonevitsky A.G., Marx U. Chip-based liver equivalents for toxicity testing - organotypicalness versus cost-efficient high throughput. Lab Chip 2013, 13:3481-3495.
30. Marx U. Trends in Cell Culture Technology, New Technologies for Toxicity Testing 2012, 26-46. Landes Bioscience.
31. Marx U., Sandig V. Drug Testing In Vitro - Breakthroughs and Trends in Cell Culture Technology 2007, Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.
32. Rueckert C., Guzmán C.A. Vaccines: from empirical development to rational design. PLoS Pathog. 2012, 8:e1003001.
33. Woodrow K.A., Bennett K.M., Lo D.D. Mucosal vaccine design and delivery. Annu. Rev. Biomed. Eng. 2012, 14:17-46.
34. Djupesland P.G. Nasal drug delivery devices: characteristics and performance in a clinical perspective-a review. Drug Deliv. Transl. Res. 2013, 3:42-62.
35. McVey D.S., Galvin J.E., Olson S.C. A review of the effectiveness of vaccine potency control testing. Int. J. Parasitol. 2003, 33:507-516.
36. Petricciani J., Egan W., Vicari G., Furesz J., Schild G. Potency assays for therapeutic live whole cell cancer vaccines. Biologicals 2007, 35:107-113.
37. Hoos A., Parmiani G., Hege K., Sznol M., Loibner H., Eggermont A., Urba W., Blumenstein B., Sacks N., Keilholz U., Nichol G. A clinical development paradigm for cancer vaccines and related biologics. J. Immunother. 2007, 30:1-15.
38. Rothenberg M.E., Hogan S.P. The eosinophil. Annu. Rev. Immunol. 2006, 24:147-174.
39. Metcalfe D.D., Baram D., Mekori Y.A. Mast cells. Physiol. Rev. 1997, 77:1033-1079.
40. Papayannopoulos V., Zychlinsky A. NETs: a new strategy for using old weapons. Trends Immunol. 2009, 30:513-521.
41. Hashimoto D., Miller J., Merad M. Dendritic cell and macrophage heterogeneity in vivo. Immunity 2011, 35:323-335.
42. Story A.C., Moore A.J., Anderson M.K. Dendritic cell development: a choose-your-own-adventure story. Adv. Hematol. 2013, 2013:1-16.
43. Villablanca E.J., Russo V., Mora J.R. Dendritic cell migration and lymphocyte homing imprinting. Histol. Histopathol. 2008, 23:897-910.
44. Chung N.P.Y., Chen Y., Chan V.S.F., Tam P.K.H., Lin C.L.S. Dendritic cells: sentinels against pathogens. Histol. Histopathol. 2004, 19(8):317-324.
45. Toebak M.J., Gibbs S., Bruynzeel D.P., Scheper R.J., Rustemeyer T. Dendritic cells: biology of the skin. Contact Dermatitis 2009, 60:2-20.
46. Lipscomb M.F., Masten B.J. Dendritic cells: immune regulators in health and disease. Physiol. Rev. 2002, 82:97-130.
47. Carbone F.R., Belz G.T., Heath W.R. Transfer of antigen between migrating and lymph node-resident DCs in peripheral T-cell tolerance and immunity. Trends Immunol. 2004, 25:655-658.
48. Colonna M. Interleukin-22-producing natural killer cells and lymphoid tissue inducer-like cells in mucosal immunity. Immunity 2009, 31:15-23.
49. Sun J.C., Beilke J.N., Lanier L.L. Adaptive immune features of natural killer cells. Nature 2009, 457:557-561.
50. Cupedo T. Human lymph node development: an inflammatory interaction. Immunol. Lett. 2011, 138:4-6.
51. Pearson C., Uhlig H.H., Powrie F. Lymphoid microenvironments and innate lymphoid cells in the gut. Trends Immunol. 2012, 33:289-296.
52. Cherrier M., Ohnmacht C., Cording S., Eberl G. Development and function of intestinal innate lymphoid cells. Curr. Opin. Immunol. 2012, 24:277-283.
53. Walker J.A., McKenzie A.N.J. Development and function of group 2 innate lymphoid cells. Curr. Opin. Immunol. 2013, 2:148-155.
54. Scanlon S.T., McKenzie A.N.J. Type 2 innate lymphoid cells: new players in asthma and allergy. Curr. Opin. Immunol. 2012, 24:707-712.
55. Shekhar S., Milling S., Yang X. Migration of γδ T cells in steady-state conditions. Vet. Immunol. Immunopathol. 2012, 147:1-5.
56. Zheng J., Liu Y., Lau Y.L., Tu W. γδ-T cells: an unpolished sword in human anti-infection immunity. Cell. Mol. Immunol. 2013, 10:50-57.
57. Caccamo N., Todaro M., Sireci G., Meraviglia S., Stassi G., Dieli F. Mechanisms underlying lineage commitment and plasticity of human γδ T cells. Cell. Mol. Immunol. 2013, 10:30-34.
58. Janeway C., Travers P., Walport M., Shlomchik M. Immunobiology: The Immune System in Health and Disease 2004, Urban & Fischer Verlag Elsevier GmbH. 6th ed.
59. Balogh P., Fisi V., Szakal A.K. Fibroblastic reticular cells of the peripheral lymphoid organs: unique features of a ubiquitous cell type. Mol. Immunol. 2008, 46:1-7.
60. Turley S.J., Fletcher A.L., Elpek K.G. The stromal and haematopoietic antigen-presenting cells that reside in secondary lymphoid organs. Nat. Rev. Immunol. 2010, 10:813-825.
61. Fletcher A.L., Malhotra D., Turley S.J. Lymph node stroma broaden the peripheral tolerance paradigm. Trends Immunol. 2011, 32:12-18.
62. Pabst O., Wahl B., Bernhardt G., Hammerschmidt S.I. Mesenteric lymph node stroma cells in the generation of intestinal immune responses. J. Mol. Med. 2009, 87:945-951.
63. Koning J.J., Mebius R.E. Interdependence of stromal and immune cells for lymph node function. Trends Immunol. 2012, 33:264-270.
64. Link A., Hardie D.L., Favre S., Britschgi M.R., Adams D.H., Sixt M., Cyster J.G., Buckley C.D., Luther S.A. Association of T-zone reticular networks and conduits with ectopic lymphoid tissues in mice and humans. Am. J. Pathol. 2011, 178:1662-1675.
65. Mueller S.N., Germain R.N. Stromal cell contributions to the homeostasis and functionality of the immune system. Nat. Rev. Immunol. 2009, 9:618-629.
66. Parsonage G., Filer A.D., Haworth O., Nash G.B., Rainger G.E., Salmon M., Buckley C.D. A stromal address code defined by fibroblasts. Trends Immunol. 2005, 26:150-156.
67. Katakai T., Suto H., Sugai M., Gonda H., Togawa A., Suematsu S., Ebisuno Y., Katagiri K., Kinashi T., Shimizu A. Organizer-like reticular stromal cell layer common to adult secondary lymphoid organs. J. Immunol. 2008, 181:6189-6200.
68. Katakai T., Hara T., Sugai M., Gonda H., Shimizu A. Lymph node fibroblastic reticular cells construct the stromal reticulum via contact with lymphocytes. J. Exp. Med. 2004, 200:783-795.
69. Pillay J., den Braber I., Vrisekoop N., Kwast L.M., de Boer R.J., Borghans J.A.M., Tesselaar K., Koenderman L. In vivo labeling with 2H2O reveals a human neutrophil lifespan of 5.4days. Blood 2010, 116:625-627.
70. Brinkmann V., Reichard U., Goosmann C., Fauler B., Uhlemann Y., Weiss D.S., Weinrauch Y., Zychlinsky A. Neutrophil extracellular traps kill bacteria. Science 2004, 303:1532-1535.
71. Eloe-Fadrosh E.A., Rasko D.A. The human microbiome: from symbiosis to pathogenesis. Annu. Rev. Med. 2013, 64:145-163.
72. Blaser M., Bork P., Fraser C., Knight R., Wang J. The microbiome explored: recent insights and future challenges. Nat. Rev. Microbiol. 2013, 11:213-217.
73. Huang Y.J., Charlson E.S., Collman R.G., Colombini-Hatch S., Martinez F.D., Senior R. The role of the lung microbiome in health and disease: a national heart, lung, and blood institute workshop report. Am. J. Respir. Crit. Care Med. 2013, 187:1382-1387.
74. Grice E.A., Segre J.A. The skin microbiome. Nat. Rev. Microbiol. 2013, 9:244-253.
75. Canny G.O., McCormick B.A. Bacteria in the intestine, helpful residents or enemies from within?. Infect. Immun. 2008, 76:3360-3373.
76. Brandtzaeg P., Kiyono H., Pabst R., Russell M. Terminology: nomenclature of mucosa-associated lymphoid tissue. Mucosal Immunol. 2008, 1:31-37.
77. Kunisawa J., Kurashima Y., Kiyono H. Gut-associated lymphoid tissues for the development of oral vaccines. Adv. Drug Deliv. Rev. 2012, 64:523-530.
78. Brandtzaeg P. Mucosal immunity: integration between mother and the breast-fed infant. Vaccine 2003, 21:3382-3388.
79. Hasenberg M., Stegemann-Koniszewski S., Gunzer M. Cellular immune reactions in the lung. Immunol. Rev. 2013, 251:189-214.
80. Leavy O. Asthma and allergy: apoptotic cell clearance lets you breathe easy. Nat. Rev. Immunol. 2013, 13:157.
81. Crosby L.M., Waters C.M. Epithelial repair mechanisms in the lung. Am. J. Physiol. Lung Cell. Mol. Physiol. 2010, 298:L715-L731.
82. Blank F., Rothen-Rutishauser B., Gehr P. Dendritic cells and macrophages form a transepithelial network against foreign particulate antigens. Am. J. Respir. Cell Mol. Biol. 2007, 36:669-677.
83. Holt P.G. Pulmonary dendritic cells in local immunity to inert and pathogenic antigens in the respiratory tract. Proc. Am. Thorac. Soc. 2005, 2:116-120.
84. Monticelli L.A., Sonnenberg G.F., Artis D. Innate lymphoid cells: critical regulators of allergic inflammation and tissue repair in the lung. Curr. Opin. Immunol. 2012, 24:284-289.
85. Auxenfans C., Fradette J., Lequeux C., Germain L., Kinikoglu B., Bechetoille N., Braye F., Auger F.A., Damour O. Evolution of three dimensional skin equivalent models reconstructed in vitro by tissue engineering. Eur. J. Dermatol. 2009, 19:107-113.
86. Metcalfe A.D., Ferguson M.W.J. Tissue engineering of replacement skin: the crossroads of biomaterials, wound healing, embryonic development, stem cells and regeneration. J. R. Soc. Interface. 2007, 4:413-437.
87. von Andrian U., Mackay C. T-cell function and migration. NEJM 2000, 343:1020-1034.
88. Muller W.A. Mechanisms of transendothelial migration of leukocytes. Circ. Res. 2009, 105:223-230.
89. Ransohoff R.M., Kivisäkk P., Kidd G. Three or more routes for leukocyte migration into the central nervous system. Nat. Rev. Immunol. 2003, 3:569-581.
90. Feng D., Nagy J.A., Dvorak H.F., Dvorak A.M. Ultrastructural studies define soluble macromolecular, particulate, and cellular transendothelial cell pathways in venules, lymphatic vessels, and tumor-associated microvessels in man and animals. Microsc. Res. Tech. 2002, 57:289-326.
91. Blum K.S., Pabst R. Keystones in lymph node development. J. Anat. 2006, 209:585-595.
92. Bousso P., Robey E. Dynamics of CD8+ T cell priming by dendritic cells in intact lymph nodes. Nat. Immunol. 2003, 4:579-585.
93. Surh C.D., Sprent J. Homeostasis of naive and memory T cells. Immunity 2008, 29:848-862.
94. Miller M.J., Safrina O., Parker I., Cahalan M.D. Imaging the single cell dynamics of CD4+ T cell activation by dendritic cells in lymph nodes. J. Exp. Med. 2004, 200:847-856.
95. Lindquist R.L., Shakhar G., Dudziak D., Wardemann H., Eisenreich T., Dustin M.L., Nussenzweig M.C. Visualizing dendritic cell networks in vivo. Nat. Immunol. 2004, 5:1243-1250.
96. Okada T., Miller M.J., Parker I., Krummel M.F., Neighbors M., Hartley S.B., O'Garra A., Cahalan M.D., Cyster J.G. Antigen-engaged B cells undergo chemotaxis toward the T zone and form motile conjugates with helper T cells. PLoS Biol. 2005, 3:e150.
97. von Andrian U.H., Mempel T.R. Homing and cellular traffic in lymph nodes. Nat. Rev. Immunol. 2003, 3:867-878.
98. Breart B., Bousso P. Cellular orchestration of T cell priming in lymph nodes. Curr. Opin. Immunol. 2006, 18:483-490.
99. Willard-Mack C.L. Normal structure, function, and histology of lymph nodes. Toxicol. Pathol. 2006, 34:409-424.
100. Mempel T.R., Junt T., von Andrian U.H. Rulers over randomness: stroma cells guide lymphocyte migration in lymph nodes. Immunity 2006, 25:867-869.
101. Mempel T.R., Henrickson S.E., Von Andrian U.H. T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature 2004, 427:154-159.
102. González P.A., Carreño L.J., Figueroa C.A., Kalergis A.M. Modulation of immunological synapse by membrane-bound and soluble ligands. Cytokine Growth Factor Rev. 2007, 18:19-31.
103. Roozendaal R., Mebius R.E., Kraal G. The conduit system of the lymph node. Int. Immunol. 2008, 20:1483-1487.
104. Bousso P. T-cell activation by dendritic cells in the lymph node: lessons from the movies. Nat. Rev. Immunol. 2008, 8:675-684.
105. El Shikh M.E.M., El Sayed R.M., Sukumar S., Szakal A.K., Tew J.G. Activation of B cells by antigens on follicular dendritic cells. Trends Immunol. 2010, 31:205-211.
106. Szakal A.K., Kosco M.H., Tew J.G. Microanatomy of lymphoid tissue during humoral immune responses: structure function relationships. Annu. Rev. Immunol. 1989, 7:91-109.
107. Shlomchik M.J., Weisel F. Germinal centers. Immunol. Rev. 2012, 247:5-10.
108. Allen C.D.C., Cyster J.G. Follicular dendritic cell networks of primary follicles and germinal centers: phenotype and function. Semin. Immunol. 2008, 20:14-25.
109. Allen C.D.C., Okada T., Cyster J. Germinal-center organization and cellular dynamics. Immunity 2007, 27:190-202.
110. Lindhout E., Koopman G., Pals S.T., de Groot C. Triple check for antigen specificity of B cells during germinal centre reactions. Immunol. Today 1997, 18:573-576.
111. Beltman J.B., Marée A.F.M., de Boer R.J. Analysing immune cell migration. Nat. Rev. Immunol. 2009, 9:789-798.
112. Hauser A.E., Junt T., Mempel T.R., Sneddon M.W., Kleinstein S.H., Henrickson S.E., von Andrian U.H., Shlomchik M.J., Haberman A.M. Definition of germinal-center B cell migration in vivo reveals predominant intrazonal circulation patterns. Immunity 2007, 26:655-667.
113. McHeyzer-Williams L.J., McHeyzer-Williams M.G. Antigen-specific memory B cell development. Annu. Rev. Immunol. 2005, 23:487-513.
114. Schwickert T.A., Lindquist R.L., Shakhar G., Livshits G., Skokos D., Kosco-Vilbois M.H., Dustin M.L., Nussenzweig M.C. In vivo imaging of germinal centres reveals a dynamic open structure. Nature 2007, 446:83-87.
115. Tarlinton D., Radbruch A., Hiepe F., Dörner T. Plasma cell differentiation and survival. Curr. Opin. Immunol. 2008, 20:1-8.
116. Radbruch A., Muehlinghaus G., Luger E.O., Inamine A., Smith K.G.C., Dörner T., Hiepe F. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat. Rev. Immunol. 2006, 6:741-750.
117. Minges Wols H.A., Underhill G.H., Kansas G.S., Witte P.L. The role of bone marrow-derived stromal cells in the maintenance of plasma cell longevity. J. Immunol. 2002, 169:4213-4221.
118. Yoshida T., Mei H., Dörner T., Hiepe F., Radbruch A., Fillatreau S., Hoyer B.F. Memory B and memory plasma cells. Immunol. Rev. 2010, 237:117-139.
119. Tokoyoda K., Radbruch A. Signals controlling rest and reactivation of T helper memory lymphocytes in bone marrow. CMLS 2012, 69:1609-1613.
120. Tokoyoda K., Zehentmeier S., Chang H.D., Radbruch A. Organization and maintenance of immunological memory by stroma niches. Eur. J. Immunol. 2009, 39:2095-2099.
121. Chu V.T., Berek C. The establishment of the plasma cell survival niche in the bone marrow. Immunol. Rev. 2013, 251:177-188.
122. Chu V.T., Beller A., Nguyen T.T.N., Steinhauser G., Berek C. The long-term survival of plasma cells. Scand. J. Immunol. 2011, 73:508-511.
123. Chu V.T., Berek C. Immunization induces activation of bone marrow eosinophils required for plasma cell survival. Eur. J. Immunol. 2012, 42:130-137.
124. Travlos G.S. Histopathology of bone marrow. Toxicol. Pathol. 2006, 34:566-598.
125. Travlos G.S. Normal structure, function, and histology of the bone marrow. Toxicol. Pathol. 2006, 34:548-565.
126. Takaku T., Malide D., Chen J., Calado R.T., Kajigaya S., Young N.S. Hematopoiesis in 3 dimensions: human and murine bone marrow architecture visualized by confocal microscopy. Blood 2013, 116:41-55.
127. Di Rosa F., Pabst R. The bone marrow: a nest for migratory memory T cells. Trends Immunol. 2005, 26:360-366.
128. Takagi M. Cell processing engineering for ex-vivo expansion of hematopoietic cells. J. Biosci. Bioeng. 2005, 99:189-196.
129. Panoskaltsis N., Mantalaris A., Wu J.H.D. Engineering a mimicry of bone marrow tissue ex vivo. J. Biosci. Bioeng. 2005, 100:28-35.
130. Nichols J.E., Niles J., Cortiella J. In vitro human bone marrow analog: clinical potential Special Report. Regen. Med. 2010, 5:289-298.
131. Cook M., Futrega K., Osiecki M., Kabiri M., Kul B., Rice A., Atkinson K., Brooke G., Michael D. Micromarrows-three-dimensional coculture of hematopoietic stem cells and mesenchymal stromal cells 1. Tissue Eng. Part C 2012, 18:319-328.
132. Jiang J., Papoutsakis E.T. Stem-cell niche based comparative analysis of chemical and nano-mechanical material properties impacting ex vivo expansion and differentiation of hematopoietic and mesenchymal stem cells. Adv. Healthc. Mater. 2013, 2:25-42.
133. Jaber A., Baker M. Assessment of the immunogenicity of different interferon beta-1a formulations using ex vivo T-cell assays. J. Pharm. Biomed. Anal. 2007, 43:1256-1261.
134. Maxwell G., Mackay C. Application of a systems biology approach to skin allergy risk assessment. ATLA 2008, 36:521-556.
135. Gibb S. Toxicity testing in the 21st century: a vision and a strategy. Reprod. Toxicol. 2008, 25:136-138.
136. Collins F.S., Gray G.M., Bucher J.R. Transforming environmental health protection. Science 2009, 319:906-907.
137. Krewski D., Westphal M., Al-Zoughool M., Croteau M.C., Andersen M.E. New directions in toxicity testing. Annu. Rev. Public Health 2011, 32:161-178.
138. Dix D.J., Houck K.A., Martin M.T., Richard A.M., Setzer R.W., Kavlock R.J. The ToxCast program for prioritizing toxicity testing of environmental chemicals. Toxicol. Sci. 2007, 95:5-12.
139. Römer P., Berr S., Avota E. Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412. Blood 2011, 118:6772-6782.
140. Engelhardt B., Wolburg H. Mini-review: transendothelial migration of leukocytes: through the front door or around the side of the house?. Eur. J. Immunol. 2004, 34:2955-2963.
141. Barfod L., Dobrilovic T., Magistrado P., Khunrae P., Viwami F., Bruun J., Dahlbäck M., Bernasconi N.L., Fried M., John D., Duffy P.E., Salanti A., Lanzavecchia A., Lim C.T., Ndam N.T., Higgins M.K., Hviid L. Chondroitin sulfate A-adhering Plasmodium falciparum-infected erythrocytes express functionally important antibody epitopes shared by multiple variants. J. Immunol. 2010, 185:7553-7561.
142. Barfod L., Dalgaard M.B., Pleman S.T., Ofori M.F., Pleass R.J., Hviid L. Evasion of immunity to Plasmodium falciparum malaria by IgM masking of protective IgG epitopes in infected erythrocyte surface-exposed PfEMP1. PNAS 2011, 108:12485-12490.
143. Kuckleburg C.J., Tilkens S., Santoso S., Newman P.J. Proteinase 3 contributes to transendothelial migration of NB1-positive neutrophils. J. Immunol. 2012, 188:2419-2426.
144. Blum K.S., Pabst R. Lymphocyte numbers and subsets in the human blood. Do they mirror the situation in all organs?. Immunol. Lett. 2007, 108:45-51.
145. Westermann J., Blaschke V., Zimmermann G., Hirschfeld U., Pabst R. Random entry of circulating lymphocyte subsets into peripheral lymph nodes and Peyer' s patches: no evidence in vivo of a tissue-specific migration of B and T lymphocytes at the level of high endothelial venules. Eur. J. Immunol. 1992, 22:2219-2223.
146. Hartung T., Blaauboer B.J., Bosgra S., Carney E., Coenen J., Conolly R.B., Corsini E., Green S., Faustman E.M., Gaspari A., Hayashi M., Wallace Hayes A., Hengstler J.G., Knudsen L.E., Knudsen T., McKim J., Pfaller W., Roggen E. An expert consortium review of the EC-commissioned report 'alternative (Non-Animal) methods for cosmetics testing: current status and future prospects - 2010'. ALTEX 2011, 28:183-209.
147. Rovida C., Martin S., Vivier M., Weltzien H.U., Roggen E. Advanced tests for skin and respiratory sensitization assessment. ALTEX 2013, 30:231-252.
148. Mehling A., Eriksson T., Eltze T., Kolle S., Ramirez T., Teubner W., van Ravenzwaay B., Landsiedel R. Non-animal test methods for predicting skin sensitization potentials. Arch. Toxicol. 2012, 86:1273-1295.
149. Vohr H.-W. Encyclopedic Reference of Immunotoxicology 2005, Springer-Verlag, Berlin/Heidelberg.
150. Lehmann P.V. Image Analysis and Data Management of ELISPOT Assay Results. Handbook of ELISPOT: Methods and Protocols 2005, 302:117-131. Humana Press Inc., Totowa.
151. Drake D.R., Singh I., Nguyen M.N., Kachurin A., Wittman V., Parkhill R., Kachurina O., Moser J.M., Burdin N., Moreau M., Mistretta N., Byers A.M., Dhir V., Tapia T.M., Vernhes C., Gangur J., Kamala T., Swaminathan N., Warren W.L. In vitro biomimetic model of the human immune system for predictive vaccine assessments. Disrupt. Sci. Technol. 2012, 1:28-40.
152. Higbee R., Byers A.M., Dhir V., Drake D., Fahlenkamp H.G., Gangur J., Kachurin A., Kachurina O., Leistritz D., Ma Y., Mehta R., Mishkin E., Moser J., Mosquera L., Nguyen M., Parkhill R., Pawar S., Poisson L., Sanchez-Schmitz G., Schanen B., Singh I., Song H., Tapia T., Warren W., Wittman V. An immunologic model for rapid vaccine assessment - a clinical trial in a test tube. ATLA 2009, 37:19-27.
153. Ma Y., Poisson L., Sanchez-Schmitz G., Pawar S., Qu C., Randolph G.J., Warren W.L., Mishkin E.M., Higbee R.G. Assessing the immunopotency of Toll-like receptor agonists in an in vitro tissue-engineered immunological model. Immunology 2010, 130:374-387.
154. Schanen B.C., Karakoti A.S., Seal S., Drake D.R., Warren W.L., Self W.T. Exposure to titanium dioxide nanomaterials provokes inflammation of an in vitro human immune construct. ACS Nano 2009, 3:2523-2532.
155. Byers A.M., Tapia T.M., Sassano E.R., Wittman V. In vitro antibody response to tetanus in the MIMIC system is a representative measure of vaccine immunogenicity. Biologicals 2009, 37:148-151.
156. Ankley G.T., Bennett R.S., Erickson R.J., Hoff D.J., Hornung M.W., Johnson R.D., Mount D.R., Nichols J.W., Russom C.L., Schmieder P.K., Serrrano J.A., Tietge J.E., Villeneuve D.L. Adverse outcome pathways: a conceptual framework to support ecotoxicology research and risk assessment. Environ. Toxicol. Chem. 2010, 29:730-741.
157. Bhattacharya S., Zhang Q., Carmichael P.L., Boekelheide K., Andersen M.E. Toxicity testing in the 21 century: defining new risk assessment approaches based on perturbation of intracellular toxicity pathways. PLoS ONE 2011, 6:e20887.
158. Judson R.S., Kavlock R.J., Setzer R.W., Hubal E.A.C., Martin M.T., Knudsen T.B., Houck K.A., Thomas R.S., Wetmore B.A., Dix D.J. Estimating toxicity-related biological pathway altering doses for high-throughput chemical risk assessment. Chem. Res. Toxicol. 2011, 24:451-462.
159. Clewell H.J., Tan Y.M., Campbell J.L., Andersen M.E. Quantitative interpretation of human biomonitoring data. Toxicol. Appl. Pharmacol. 2008, 231:122-133.
160. Thomas R.S., Black M.B., Li L., Healy E., Chu T.M., Bao W., Andersen M.E., Wolfinger R.D. A comprehensive statistical analysis of predicting in vivo hazard using high-throughput in vitro screening. Toxicol. Sci. 2012, 128:398-417.
161. De Buck S.S., Mackie C.E. Physiologically based approaches towards the prediction of pharmacokinetics: in vitro-in vivo extrapolation. Expert Opin. Drug Metab. Toxicol. 2007, 3:865-878.
162. Caldwell G.W., Yan Z., Tang W., Dasgupta M., Hasting B. ADME optimization and toxicity assessment in early- and late-phase drug discovery. Curr. Top. Med. Chem. 2009, 9:965-980.
163. Wetmore B.A., Wambaugh J.F., Ferguson S.S., Sochaski M.A., Rotroff D.M., Freeman K., Clewell H.J., Dix D.J., Andersen M.E., Houck K.A., Allen B., Judson R.S., Singh R., Kavlock R.J., Richard A.M., Thomas R.S. Integration of dosimetry, exposure, and high-throughput screening data in chemical toxicity assessment. Toxicol. Sci. 2012, 125:157-174.
164. Rotroff D.M., Wetmore B.A., Dix D.J., Ferguson S.S., Clewell H.J., Houck K.A., Lecluyse E.L., Andersen M.E., Judson R.S., Smith C.M., Sochaski M.A., Kavlock R.J., Boellmann F., Martin M.T., Reif D.M., Wambaugh J.F., Thomas R.S. Incorporating human dosimetry and exposure into high-throughput in vitro toxicity screening. Toxicol. Sci. 2010, 117:348-358.
165. Hays S.M., Aylward L.L., LaKind J.S., Bartels M.J., Barton H.A., Boogaard P.J., Brunk C., DiZio S., Dourson M., Goldstein D.A., Lipscomb J., Kilpatrick M.E., Krewski D., Krishnan K., Nordberg M., Okino M., Tan Y.M., Viau C., Yager J.W. Guidelines for the derivation of biomonitoring equivalents: report from the biomonitoring equivalents expert workshop. RTP 2008, 51:S16-S26.
166. Fell H.B., Robison R. The growth, development and phosphatase activity of embryonic avian femora abd limb-buds cultivated in vitro. Biochem. J. 1929, 23:767-788.
167. Park T.H., Shuler M.L. Integration of cell culture and microfabrication technology. Biotechnol. Prog. 2003, 19:243-253.
168. Andersson H., van den Berg A. Microfabrication and microfluidics for tissue engineering: state of the art and future opportunities. Lab Chip 2004, 4:98-103.
169. Kim L., Toh Y.C., Voldman J., Yu H. A practical guide to microfluidic perfusion culture of adherent mammalian cells. Lab Chip 2007, 7:681-694.
170. Wu M.H., Huang S.-B., Lee G.B. Microfluidic cell culture systems for drug research. Lab Chip 2010, 10:939-956.
171. Kim H.J., Huh D., Hamilton G., Ingber D.E. Human gut-on-a-chip inhabited by microbial flora that experiences intestinal peristalsis-like motions and flow. Lab Chip 2012, 12:2165-2174.
172. Egeghy P.P., Judson R., Gangwal S., Mosher S., Smith D., Vail J., Cohen Hubal E.A. The exposure data landscape for manufactured chemicals. Sci. Total Environ. 2012, 414:159-166.
173. Pawankar R., Canonica G.W., Holgate S.T., Lockey R.F. WAO White Book on Allergy 2011-2012 2011.
174. Wirtz S., Neurath M.F. Mouse models of inflammatory bowel disease. Adv. Drug Deliv. Rev. 2007, 59:1073-1083.
175. Leonard F., Collnot E., Lehr C. A three-dimensional coculture of enterocytes, monocytes and dendritic cells to model inflamed intestinal mucosa in vitro. Mol. Pharm. 2010, 7:2103-2119.
176. Leonard F., Ali H., Collnot E.M., Crielaard B.J., Lammers T., Storm G., Lehr C.M. Screening of budesonide nanoformulations for treatment of inflammatory bowel disease in an inflamed 3D cell-culture model. ALTEX 2012, 29:275-285.
177. Tanoue T., Nishitani Y., Kanazawa K., Hashimoto T., Mizuno M. In vitro model to estimate gut inflammation using co-cultured Caco-2 and RAW264.7 cells. Biochem. Biophys. Res. Commun. 2008, 374:565-569.
178. des Rieux A., Fievez V., Théate I., Mast J., Préat V., Schneider Y.J. An improved in vitro model of human intestinal follicle-associated epithelium to study nanoparticle transport by M cells. Eur. J. Pharm. Sci. 2007, 30:380-391.
179. Spottl T., Hausmann M., Gunckel M., Herfarth H., Herlyn M., Schoelmerich J., Rogler G. A new organotypic model to study cell interactions in the intestinal mucosa. Eur. J. Gastroenterol. Hepatol. 2006, 18:901-909.
180. Ramadan Q., Jafarpoorchekab H., Huang C., Silacci P., Carrara S., Koklü G., Ghaye J., Ramsden J., Ruffert C., Vergeres G., Gijs M.A.M. NutriChip: nutrition analysis meets microfluidics. Lab Chip 2013, 13:196-203.
181. Pope C.A., Dockery D.W. Review of epidemiological evidence. Inhal. Toxicol. 1995, 7:1-18.
182. Lighty J.S., Veranth J.M., Sarofim A.F. Combustion aerosols: factors governing their size and composition and implications to human health. J. Air Waste Manag. Assoc. 2000, 50:1565-1618.
183. Araujo J.A., Barajas B., Kleinman M., Wang X., Bennett B.J., Gong K.W., Navab M., Harkema J., Sioutas C., Lusis A.J., Nel A.E. Ambient particulate pollutants in the ultrafine range promote early atherosclerosis and systemic oxidative stress. Circ. Res. 2008, 102:589-596.
184. Rothen-Rutishauser B., Blank F., Mühlfeld C., Gehr P. In vitro models of the human epithelial airway barrier to study the toxic potential of particulate matter. Expert Opin. Drug Metab. Toxicol. 2008, 4:1075-1089.
185. Horvath K.M., Brighton L.E., Zhang W., Carson J.L., Jaspers I. Epithelial cells from smokers modify dendritic cell responses in the context of influenza infection. Am. J. Respir. Cell Mol. Biol. 2011, 45:237-245.
186. Holmes A., Brown R., Shakesheff K. Engineering tissue alternatives to animals: applying tissue engineering to basic research and safety testing. Regen. Med. 2009, 4:579-592.
187. Rothen-Rutishauser B.M., Kiama S.G., Gehr P. A three-dimensional cellular model of the human respiratory tract to study the interaction with particles. Am. J. Respir. Cell Mol. Biol. 2005, 32:281-289.
188. Lieber M., Smith B., Szakal A., Nelson-rees W., Todaro G. A continuous tumor-cell line from a human lung carcinoma with properties of type II alveolar epithelial cells. Int. J. Cancer 1976, 70:62-70.
189. Huh D., Matthews B.D., Mammoto A., Montoya-Zavala M., Hsin H.Y., Ingber D.E. Reconstituting organ-level lung functions on a chip. Science 2010, 328:1662-1668.
190. Huh D., Leslie D.C., Matthews B.D., Fraser J.P., Jurek S., Hamilton G.A., Thorneloe K.S., McAlexander M.A., Ingber D.E. A human disease model of drug toxicity-induced pulmonary oedema in a lung-on-a-chip microdevice. Sci. Transl. Med. 2012, 4:159ra147.
191. Chau D.Y.S., Johnson C., Macneil S., Haycock J.W., Ghaemmaghami A.M. The development of a 3D immunocompetent model of human ski. Biofabrication 2013, 5:035011.
192. Kuper C.F., Stierum R.H., Boorsma A., Schijf M.A., Prinsen M., Bruijntjes J.P., Bloksma N., Arts J.H.E. The contact allergen dinitrochlorobenzene (DNCB) and respiratory allergy in the Th2-prone Brown Norway rat. Toxicology 2008, 246:213-221.
193. Sakaguchi H., Ashikaga T., Miyazawa M., Kosaka N., Ito Y., Yoneyama K., Sono S., Itagaki H., Toyoda H., Suzuki H. The relationship between CD86/CD54 expression and THP-1 cell viability in an in vitro skin sensitization test--human cell line activation test (h-CLAT). Cell Biol. Toxicol. 2009, 25:109-126.
194. Hooyberghs J., Schoeters E., Lambrechts N., Nelissen I., Witters H., Schoeters G., Van Den Heuvel R. A cell-based in vitro alternative to identify skin sensitizers by gene expression. Toxicol. Appl. Pharmacol. 2008, 231:103-111.
195. Azam P., Peiffer J.L., Chamousset D., Tissier M.H., Bonnet P.A., Vian L., Fabre I., Ourlin J.C. The cytokine-dependent MUTZ-3 cell line as an in vitro model for the screening of contact sensitizers. Toxicol. Appl. Pharmacol. 2006, 212:14-23.
196. Fentem J.H., Briggs D., Chesné C., Elliott G.R., Harbell J.W., Heylings J.R., Portes P., Roguet R., van de Sandt J.J., Botham P.A. A prevalidation study on in vitro tests for acute skin irritation: results and evaluation by the Management Team. Toxicol. In Vitro 2001, 15:57-93.
197. Ataç B., Wagner I., Horland R., Lauster R., Marx U., Tonevitsky A.G., Azar R.P., Lindner G. Skin and hair on-a-chip: in vitro skin models versus ex vivo tissue maintenance with dynamic perfusion. Lab Chip 2013, 13:3555-3561.
198. Wagner I., Materne E.M., Brincker S., Süßbier U., Frädrich C., Busek M., Sonntag F., Sakharov D.A., Trushkin E.V., Tonevitsky A.G., Lauster R., Marx U. A dynamic multi-organ-chip for long-term cultivation and substance testing proven by 3D human liver and skin tissue co-culture. Lab Chip 2013, 13:3435-3766.
199. Cupedo T., Stroock A., Coles M. Application of tissue engineering to the immune system: development of artificial lymph nodes. Front. Immunol. 2012, 3:343.
200. Giese C., Demmler C.D., Ammer R., Hartmann S., Lubitz A., Miller L., Müller R., Marx U. A human lymph node in vitro-challenges and progress. Artif. Organs 2006, 30:803-808.
201. Giese C., Lubitz A., Demmler C.D., Reuschel J., Bergner K., Marx U. Immunological substance testing on human lymphatic micro-organoids in vitro. J. Biotechnol. 2010, 148:38-45.
202. Seifert M., Lubitz A., Trommer J., Könnig D., Korus G., Marx U., Volk H., Duda G., Kasper G., Lehmann K., Stolk M., Giese C. Crosstalk between immune cells and mesenchymal stromal cells in a 3D bioreactor system. Int. J. Artif. Organs 2012, 35:986-995.
203. Di Maggio N., Piccinini E., Jaworski M., Trumpp A., Wendt D.J., Martin I. Toward modeling the bone marrow niche using scaffold-based 3D culture systems. Biomaterials 2011, 32:321-329.
204. Wendt D., Marsano A., Jakob M., Heberer M., Martin I. Oscillating perfusion of cell suspensions through three-dimensional scaffolds enhances cell seeding efficiency and uniformity. Biotechnol. Bioeng. 2003, 84:205-214.
205. Wendt D., Stroebel S., Jakob M., John G.T., Martin I. Uniform tissues engineered by seeding and culturing cells in 3D scaffolds under perfusion at defined oxygen tensions. Biorheology 2006, 43:481-488.
206. Papadimitropoulos A., Scherberich A., Güven S., Theilgaard N., Crooijmans H.J.A., Santini F., Scheffler K., Zallone A., Martin I. A 3D in vitro bone organ model using human progenitor cells. Eur. Cell Mater. 2011, 21:445-458.
207. Peyton S.R., Kalcioglu Z.I., Cohen J.C., Runkle A.P., Van Vliet K.J., Lauffenburger D., Griffith L.G. Marrow-derived stem cell motility in 3D synthetic scaffold is governed by geometry along with adhesivity and stiffness. Biotechnol. Bioeng. 2011, 108:1181-1193.
208. Thieme S., Ryser M., Gentsch M., Navratiel K., Brenner S., Stiehler M., Ro J., Gelinsky M., Ro A. Stromal cell-derived factor-1a - directed chemoattraction. Tissue Eng. Part C 2009, 15:687-696.
209. Junt T., Scandella E., Ludewig B. Form follows function: lymphoid tissue microarchitecture in antimicrobial immune defence. Nat. Rev. Immunol. 2008, 8:764-775.
210. Sixt M., Kanazawa N., Selg M., Samson T., Roos G., Reinhardt D.P., Pabst R., Lutz M.B., Sorokin L. The conduit system transports soluble antigens from the afferent lymph to resident dendritic cells in the T cell area of the lymph node. Immunity 2005, 22:19-29.
211. Friedl P., Weigelin B. Interstitial leucocyte migration and immune function. Nat. Immunol. 2008, 9:960-969.
212. Hattersley S.M., Dyer C.E., Greenman J., Haswell S.J. Development of a microfluidic device for the maintenance and interrogation of viable tissue biopsies. Lab Chip 2008, 8:1842-1846.
213. van Midwoud P.M., Merema M.T., Verweij N., Groothuis G.M.M., Verpoorte E. Hydrogel embedding of precision-cut liver slices in a microfluidic device improves drug metabolic activity. Biotechnol. Bioeng. 2011, 108:1404-1412.
214. Schumacher K., Khong Y.M., Chang S., Ni J., Sun W., Yu H. Perfusion culture improves the maintenance of cultured liver tissue slices. Tissue Eng. 2007, 13:197-205.
215. Mestres P., Morguet A., Schmidt W., Kob A., Thedinga E. A new method to assess drug sensitivity on breast tumor acute slices preparation. Ann. N. Y. Acad. Sci. 2006, 1091:460-469.
216. Tanaka T., Ebisuno Y., Kanemitsu N., Umemoto E., Yang B., Jang M., Miyasaka M. Molecular determinants controlling homeostatic recirculation and tissue-specific trafficking of lymphocytes. Int. Arch. Allergy Immunol. 2004, 134:120-134.
217. Arck P.C., Gilhar A., Bienenstock J., Paus R. The alchemy of immune privilege explored from a neuroimmunological perspective. Curr. Opin. Pharmacol. 2008, 8:480-489.
218. Miyasaka M., Tanaka T. Lymphocyte trafficking across high endothelial venules: dogmas and enigmas. Nat. Rev. Immunol. 2004, 4:360-370.
219. Cinamon G., Shinder V., Alon R. Shear forces promote lymphocyte migration across vascular endothelium bearing apical chemokines. Nat. Immunol. 2001, 2:515-522.
220. De Groot A.S., Moise L. Prediction of immunogenicity for therapeutic proteins: state of the art. Curr. Opin. Drug Discov. Dev. 2007, 10:332-340.
221. De Groot A.S., McMurry J., Moise L. Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates. Curr. Opin. Pharmacol. 2008, 8:620-626.
222. Hellendoorn K., Jones T., Watkins J., Baker M., Hamilton A., Carr F. T-cell epitopes (DeImmunisation™). Cancer Cell Int. 2004, 1:100.
223. Sweeney L.M., Shuler M.L., Babish J.G., Ghanem A. A cell culture analogue of rodent physiology: application to naphthalene toxicology. Toxicol. In Vitro 1995, 9:307-316.
224. Huh D., Hamilton G.A., Ingber D.E. From 3D cell culture to organs-on-chips. Trends Cell Biol. 2011, 21:745-754.
225. Marx U., Walles H., Hoffmann S., Lindner G., Horland R., Sonntag F., Klotzbach U., Sakharov D., Tonevitsky A., Lauster R. 'Human-on-a-chip' developments: a translational cutting-edge alternative to systemic safety assessment and efficiency evaluation of substances in laboratory animals and man?. ATLA 2012, 40:235-257.
226. Shuler M.L. Modeling life. Ann. Biomed. Eng. 2012, 40:1399-1407.
227. van de Stolpe A., den Toonder J. Workshop meeting report organs-on-chips: human disease models. Lab Chip 2013, 13:3449-3470.
228. Mebius R.E., Kraal G. Structure and function of the spleen. Nat. Rev. Immunol. 2005, 5:606-616.
229. Blackman B.R., García-Cardeña G., Gimbrone M.A. A new in vitro model to evaluate differential responses of endothelial cells to simulated arterial shear stress waveforms. J. Biomech. Eng. 2002, 124:397.
230. Traggiai E., Chicha L., Mazzucchelli L., Bronz L., Piffaretti J.C., Lanzavecchia A., Manz M.G. Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 2004, 304:104-107.
231. Ishikawa F., Yasukawa M., Lyons B., Yoshida S., Miyamoto T., Yoshimoto G., Watanabe T., Akashi K., Shultz L.D., Harada M. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor gamma chain(null) mice. Blood 2005, 106:1565-1573.
232. Kobayashi Y., Watanabe T. Synthesis of artificial lymphoid tissue with immunological function. Trends Immunol. 2010, 31:422-428.
233. Pancrazio J.J., Wang F., Kelley C.A. Enabling tools for tissue engineering. Biosens. Bioelectron. 2007, 22:2803-2811.
234. Adams R.H., Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat. Rev. Mol. Cell Biol. 2007, 8:464-478.
235. Affolter M., Zeller R., Caussinus E. Tissue remodelling through branching morphogenesis. Nat. Rev. Mol. Cell Biol. 2009, 10:831-842.
236. Nelson C.M., Gleghorn J.P. Sculpting organs: mechanical regulation of tissue development. Annu. Rev. Biomed. Eng. 2011, 14:129-154.
237. Tian L., George S.C. Biomaterials to prevascularize engineered tissues. J. Cardiovasc. Transl. Res. 2011, 4:685-698.
238. Montaño I., Schiestl C., Schneider J., Pontiggia L., Luginbühl J., Biedermann T., Böttcher-Haberzeth S., Braziulis E., Meuli M., Reichmann E. Formation of human capillaries in vitro: the engineering of prevascularized matrices. Tissue Eng. Part A 2010, 16:269-282.
239. Mertsching H., Walles T., Hofmann M., Schanz J., Knapp W.H. Engineering of a vascularized scaffold for artificial tissue and organ generation. Biomaterials 2005, 26:6610-6617.
240. Scheller K. Upcyte microvascular endothelial cells repopulate. Tissue Eng. Part C 2013, 19:57-67.
241. Heine J., Schmiedl A., Cebotari S., Karck M., Mertsching H., Haverich A., Kallenbach K. Tissue engineering human small-caliber autologous vessels using a xenogenous decellularized connective tissue matrix approach: preclinical comparative biomechanical studies. Artif. Organs 2011, 35:930-940.
242. Norotte C., Marga F.S., Niklason L.E., Forgacs G. Scaffold-free vascular tissue engineering using bioprinting. Biomaterials 2009, 30:5910-5917.
243. Miller J.S., Stevens K.R., Yang M.T., Baker B.M., Nguyen D.H.T., Cohen D.M., Toro E., Chen A., Galie P., Yu X., Chaturvedi R., Bhatia S.N., Chen C.S. Rapid casting of patterned vascular networks for perfusable engineered three-dimensional tissues. Nat. Mater. 2012, 11:1-7.
244. Schimek K., Busek M., Brincker S., Groth B., Hoffmann S., Lauster R., Lindner G., Lorenz A., Menzel U., Sonntag F., Walles H., Marx U., Horland R. Integrating biological vasculature into a multi-organ-chip microsystem. Lab Chip 2013, 13:3588-3598.
245. Günther A., Yasotharan S., Vagaon A., Lochovsky C., Pinto S., Yang J., Lau C., Voigtlaender-Bolz J., Bolz S.S. A microfluidic platform for probing small artery structure and function. Lab Chip 2010, 10:2341-2349.
246. Ootani A., Li X., Sangiorgi E., Ho Q.T., Ueno H., Toda S., Sugihara H., Fujimoto K., Weissman I.L., Capecchi M.R., Kuo J. Sustained in vitro intestinal epithelial culture within a Wnt-dependent stem cell niche. Nat. Med. 2010, 15:701-706.